$CKPT
Checkpoint Therapeutics, Inc.

2022 Q1 Form 10-Q Financial Statement

#000141057822001386 Filed on May 12, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $52.00K $70.00K
YoY Change -25.71% -92.78%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.243M $2.370M
YoY Change -5.36% 41.07%
% of Gross Profit
Research & Development $14.67M $4.213M
YoY Change 248.21% 59.89%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $16.91M $6.586M
YoY Change 156.8% 52.7%
Operating Profit -$16.86M -$6.518M
YoY Change 158.68% 95.09%
Interest Expense $13.00K $10.00K
YoY Change 30.0% -83.33%
% of Operating Profit
Other Income/Expense, Net $13.00K $13.00K
YoY Change 0.0% -78.33%
Pretax Income -$16.85M -$6.510M
YoY Change 158.8% 98.48%
Income Tax
% Of Pretax Income
Net Earnings -$16.85M -$6.505M
YoY Change 159.0% 98.26%
Net Earnings / Revenue -32400.0% -9292.86%
Basic Earnings Per Share -$0.20 -$0.09
Diluted Earnings Per Share $0.20 $0.09
COMMON SHARES
Basic Shares Outstanding 85.05M 70.30M
Diluted Shares Outstanding 85.05M 70.30M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $41.48M $60.03M
YoY Change -30.91% 179.47%
Cash & Equivalents $41.48M $60.03M
Short-Term Investments
Other Short-Term Assets $52.00K $68.00K
YoY Change -23.53% -90.93%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $42.91M $61.43M
YoY Change -30.15% 164.67%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $42.91M $61.43M
Total Long-Term Assets $0.00 $0.00
Total Assets $42.91M $61.43M
YoY Change -30.15% 164.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.859M $3.528M
YoY Change 179.45% 52.73%
Accrued Expenses $339.0K $160.0K
YoY Change 111.88% 33.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $22.69M $7.255M
YoY Change 212.75% 3.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $22.69M $7.255M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $22.69M $7.255M
YoY Change 212.75% 3.79%
SHAREHOLDERS EQUITY
Retained Earnings -$216.7M -$149.7M
YoY Change 44.76%
Common Stock $7.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $20.22M $54.18M
YoY Change
Total Liabilities & Shareholders Equity $42.91M $61.43M
YoY Change -30.15% 164.67%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$16.85M -$6.505M
YoY Change 159.0% 98.26%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$19.61M -$4.657M
YoY Change 321.0% 2.58%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.347M 23.92M
YoY Change -73.46% -42810.71%
NET CHANGE
Cash From Operating Activities -19.61M -4.657M
Cash From Investing Activities
Cash From Financing Activities 6.347M 23.92M
Net Change In Cash -13.26M 19.26M
YoY Change -168.84% -519.08%
FREE CASH FLOW
Cash From Operating Activities -$19.61M -$4.657M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.20
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.09
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
85049895
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70303387
CY2022Q1 ckpt Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm
P0Y
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P0Y
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001651407
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
77574405
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
83801242
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P0Y
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
135000000
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-38128
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
CHECKPOINT THERAPEUTICS, INC.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-2568632
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
95 Sawyer Road
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 110
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02453
CY2022Q1 dei City Area Code
CityAreaCode
781
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
652-4500
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2022Q1 dei Trading Symbol
TradingSymbol
CKPT
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41476000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54735000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1378000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
976000
CY2022Q1 us-gaap Other Assets Current
OtherAssetsCurrent
52000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
17000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
42906000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
55728000
CY2022Q1 us-gaap Assets
Assets
42906000
CY2021Q4 us-gaap Assets
Assets
55728000
CY2022Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
21675000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
24919000
CY2022Q1 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
1015000
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
1063000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
22690000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25982000
CY2022Q1 us-gaap Liabilities
Liabilities
22690000
CY2021Q4 us-gaap Liabilities
Liabilities
25982000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
135000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83801242
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
77574405
CY2022Q1 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
0
CY2021Q4 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
2121422
CY2021Q4 us-gaap Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
6598000
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
236917000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
223001000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-216710000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-199862000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
20216000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
29746000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42906000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55728000
CY2022Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
52000
CY2021Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
68000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14670000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4213000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2243000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2373000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
16913000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
6586000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-16861000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6518000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
13000
CY2021Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
13000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
13000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
13000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-16848000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-6505000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.09
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
85049895
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70303387
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
29746000
CY2022Q1 ckpt Stock Issued During Period Value Common Shares For At The Market Offering
StockIssuedDuringPeriodValueCommonSharesForAtTheMarketOffering
8045000
CY2022Q1 ckpt Stock Issued During Period Value Common Shares For Services
StockIssuedDuringPeriodValueCommonSharesForServices
196000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
775000
CY2022Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
1698000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-16848000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
20216000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
35379000
CY2021Q1 ckpt Stock Issued During Period Value Common Shares For At The Market Offering
StockIssuedDuringPeriodValueCommonSharesForAtTheMarketOffering
23893000
CY2021Q1 ckpt Stock Issued During Period Value Common Shares For Services
StockIssuedDuringPeriodValueCommonSharesForServices
634000
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
774000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-6505000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
54175000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-16848000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-6505000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
775000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
774000
CY2022Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
196000
CY2021Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
634000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
402000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-475000
CY2022Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
35000
CY2021Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
48000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3292000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
13000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19606000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4657000
CY2022Q1 ckpt Proceeds From Issuance Of Common Stock For At Market Offering
ProceedsFromIssuanceOfCommonStockForAtMarketOffering
8209000
CY2021Q1 ckpt Proceeds From Issuance Of Common Stock For At Market Offering
ProceedsFromIssuanceOfCommonStockForAtMarketOffering
24569000
CY2022Q1 ckpt Payment Of Stock Offering Costs
PaymentOfStockOfferingCosts
164000
CY2021Q1 ckpt Payment Of Stock Offering Costs
PaymentOfStockOfferingCosts
651000
CY2022Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1698000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6347000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23918000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13259000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
19261000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54735000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40772000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41476000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60033000
CY2022Q1 us-gaap Stock Issued1
StockIssued1
6598000
CY2021Q1 us-gaap Stock Issued1
StockIssued1
4617000
CY2021Q1 ckpt Stock Issued Under Public Offering Costs Not Paid
StockIssuedUnderPublicOfferingCostsNotPaid
25000
CY2022Q1 ckpt Significant Accounting Policies Policy Textblock
SignificantAccountingPoliciesPolicyTextblock
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Significant<span style="font-style:normal;font-weight:normal;"> </span>Accounting<span style="font-style:normal;font-weight:normal;"> </span>Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">There have been no material changes in the Company’s significant accounting policies to those previously disclosed in the 2021 Annual Report on Form 10-K.</span></p>
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-216700000
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2015Q1 ckpt Equity Method Investment Annual Equity Fee Percentage
EquityMethodInvestmentAnnualEquityFeePercentage
0.025
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3729084
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4503838
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0271
CY2021Q2 ckpt Common Stock Increase In Shares Authorized
CommonStockIncreaseInSharesAuthorized
40000000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
135000000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 ckpt Shelf Registration Statement Maximum Authorized Securities
ShelfRegistrationStatementMaximumAuthorizedSecurities
100000000
CY2022Q1 ckpt Shelf Registration Statement Remaining Authorized Securities
ShelfRegistrationStatementRemainingAuthorizedSecurities
46400000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.14
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M8D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0104
CY2022Q1 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
775000
CY2021Q1 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
774000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
9859000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
16139000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
339000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
843000
CY2022Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
11180000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
7704000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
297000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
233000
CY2022Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
21675000
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
24919000

Files In Submission

Name View Source Status
0001410578-22-001386-index-headers.html Edgar Link pending
0001410578-22-001386-index.html Edgar Link pending
0001410578-22-001386.txt Edgar Link pending
0001410578-22-001386-xbrl.zip Edgar Link pending
ckpt-20220331.xsd Edgar Link pending
ckpt-20220331x10q.htm Edgar Link pending
ckpt-20220331x10q_htm.xml Edgar Link completed
ckpt-20220331xex31d1.htm Edgar Link pending
ckpt-20220331xex31d2.htm Edgar Link pending
ckpt-20220331xex32d1.htm Edgar Link pending
ckpt-20220331xex32d2.htm Edgar Link pending
ckpt-20220331_cal.xml Edgar Link unprocessable
ckpt-20220331_def.xml Edgar Link unprocessable
ckpt-20220331_lab.xml Edgar Link unprocessable
ckpt-20220331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending